Evidence map›Paper›PMID 41091425›Full record

ArticleDiscover oncology2025

Pan-cancer analysis of INHBA indicates its potential prognostic value and correlation with HNSC and LIHC.

Shumin Li, Beibei Xu, Guanghui Wang, Luan Xu, Liya Ding, Xiaopei Wu, Baoying Zheng, Yuefeng Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shumin Li *Department of Otolaryngology-Head & Neck Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, 233004, Anhui, China.
Beibei Xu *Department of Otolaryngology-Head & Neck Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, 233004, Anhui, China.ORCID https://orcid.org/0009-0002-5221-0336
Guanghui WangDepartment of Otolaryngology-Head & Neck Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, 233004, Anhui, China.
Luan XuDepartment of Otolaryngology-Head & Neck Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, 233004, Anhui, China.
Liya DingDepartment of Otolaryngology-Head & Neck Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, 233004, Anhui, China.
Xiaopei WuDepartment of Otolaryngology-Head & Neck Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, 233004, Anhui, China.
Baoying ZhengDepartment of Otolaryngology-Head & Neck Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, 233004, Anhui, China.
Yuefeng HanDepartment of Otolaryngology-Head & Neck Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, 233004, Anhui, China. Hanyf1015@126.com.ORCID http://orcid.org/0000-0002-1277-6207

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundINHBA is a member of the TGF-β superfamily and is overexpressed in a variety of cancers and affects prognosis.However, its pan-cancer expression profile and specific roles in HNSC and LIHC remain poorly understood.

methodsWe used several databases such as TCGA to study the pan-cancer effects of INHBA, including the expression of INHBA and its correlation with clinical survival, immune checkpoints, tumor stemness scores, prognostic value, immunomodulators, genomic profiles, immune profiling, immunotherapy and functional enrichment; and further analyzed its relationship with HNSC and LIHC.

resultsFirst, we observed that the expression level of INHBA was elevated in most tumor tissues compared to non-tumor tissues, and that high expression of INHBA may have a higher prognostic value in some cancers. In addition, INHBA was significantly associated with immune checkpoints, immunomodulators, prognosis, immunomodulatory genes, tumor stemness score, cellular functional status, and immune infiltration in most tumors. Finally, further analysis of INHBA-associated gene enrichment, mutation sites and types, RNA modifications, and genomic heterogeneity showed that the main mutation types of INHBA were missense mutations and that INHBA played a very important role in HNSC and LIHC; and immunotherapy analysis also suggested that low expression of INHBA might result in better specific immunotherapy response.

conclusionThis study comprehensively reveals the important functions of INHBA in different types of cancer. It also has the potential to identify INHBA as a potential biomarker for predicting treatment response. This may help us better understand how INHBA works in cancer and provide valuable insights for developing personalized treatments.

Indexed as

HNSCImmunotherapyINHBALIHCPan-cancerPrognosis

Identifiers

PMID41091425
PMCPMC12528627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.